Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate, Copaxone®, and TV-5010, Protiramer) in Rats and Monkeys

Toxicologic Pathology

Volumn 40, Issue 1, 2012, Pages 40-54

  Ramot, Yuval ^a   Rosenstock, Moti ^b   Klinger, Ety ^b   Bursztyn, Dizza ^b   Nyska, Abraham ^c   Shinar, Doron M ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEVA PHARMACEUTICALS   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

glatiramer acetate; glatiramoids; injection site; protiramer; toxicity

Indexed keywords

GLATIRAMER; PROTIRAMER; TV 5010; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSIS; HAPLORHINI; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER FIBROSIS; LOW DRUG DOSE; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; KIDNEY DISEASES; LIVER CIRRHOSIS; MACACA FASCICULARIS; MALE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS, CHRONIC;

MACACA FASCICULARIS; RATTUS;

EID: 84856144463     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311424169     Document Type: Article

References (31)

1. Arnon R. Aharoni R. (2009). Neuroprotection and neurogeneration in MS and its animal model EAE affected by glatiramer acetate. J Neural Transm 116, 1443–49.
2. Blanchette F. Neuhaus O. (2008). Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 255(Suppl 1), 26–36.
3. Brook I. (2008). Microbiology and management of soft tissue and muscle infections. Int J Surg, 6, 328–38.
4. Cushman J. R. Richter W. R. Duke J. T. (1989). Effects of skin sensitization test wrapping on guinea pigs. Contact Derm 21, 279–80.
5. De Stefano N. Filippi M. Confavreux C. Vermersch P. Simu M. Sindic C. Hupperts R. Bajenaru O. Edan G. Grimaldi L. Marginean I. Medaer R. Orefice G. Pascu I. Pelletier J. Sanders E. Scarpini E. Mancardi G. L. (2009). The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult Scler 15, 238–43.
6. Drago F. Brusati C. Mancardi G. Murialdo A. Rebora A. (1999). Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 135, 1277–78.
7. Edgar C. M. Brunet D. G. Fenton P. McBride E. V. Green P. (2004). Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 31, 58–63.
8. Engelhardt J. A. (2008). Predictivity of animal studies for human injection site reactions with parenteral drug products. Exp Toxicol Pathol 60, 323–27.
9. Hard G. C. Johnson K. J. Cohen S. M. (2009). A comparison of rat chronic progressive nephropathy with human renal disease-implications for human risk assessment. Crit Rev Toxicol 39, 332–46.
10. Hwang L. Orengo I. (2001). Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 68, 287–88.
11. Johnson K. P. (2010). Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Exp Opin Drug Metab Toxicol, 6, 643–60.
12. Jolly H. Simpson K. Bishop B. Hunter H. Newell C. Denney D. Oleen-Burkey M. (2008). Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. J Neurosci Nurs 40, 232–39.
13. Kovalchin J. Krieger J. Collins K. Genova M. Augustyniak M. Masci A. Avril T. Gandon G. Patat A. Fauchoux N. Toutin C. Lacoste E. Patel U. Mascioli E. Zanelli E. (2011). Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers. J Clin Pharmacol 51, 649–60.
14. Kovalchin J. Krieger J. Genova M. Collins K. Augustyniak M. Masci A. Hittinger T. Kuca B. Edan G. Braudeau C. Rimbert M. Patel U. Mascioli E. Zanelli E. (2010). Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. J Neuroimmunol 225, 153–63.
15. Langer-Gould A. Moses H. H. Murray T. J. (2004). Strategies for managing the side effects of treatments for multiple sclerosis. Neurology, 63, S35–41.
16. Liblau R. (2009). Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J Neurol Sci 287(Suppl 1), S17–23.
17. Mancardi G. L. Murialdo A. Drago F. Brusati C. Croce R. Inglese M. Ratto S. (2000). Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 247, 220–21.
18. Mitchell R. N. (2004). Hemodynamic disorders, thromboembolic disease, and shock. In: Robbins and Cotran Pathologic Basis of Disease (Kumar V. Abbas A. K. A. K. Fausto N., eds.), 7th ed., pp. 119–44. Saunders Elsevier, Philadelphia, PA.
19. Nyska A. Waner T. Wormser U. Gur E. Kuttin E. Dayan D. (1992). Possible pitfalls in rat extended dermal toxicity testing: an hepatic-ocular syndrome. Arch Toxicol 66, 339–46.
20. Parker G. A. Gibson W. B. (1995). Liver lesions in rats associated with wrapping of the torso. Toxicol Pathol 23, 507–12.
21. Pichler W. J. (2003). Delayed drug hypersensitivity reactions. Ann Intern Med 139, 683–93.
22. Popper H. Schaffner F. (1957). Liver: Structure and Function. McGraw-Hill, New York.
23. Posadas S. J. Pichler W. J. (2007). Delayed drug hypersensitivity reactions—new concepts. Clin Exp Allergy 37, 989–99.
24. Sanmartin O. Requena C. Requena L. (2008). Factitial panniculitis. Dermatol Clin 26, 519–27, viii.
25. Schrempf W. Ziemssen T. (2007). Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6, 469–75.
26. Shackelford C. Long G. Wolf J. Okerberg C. Herbert R. (2002). Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 30, 93–96.
27. Soares Almeida L. M. Requena L. Kutzner H. Angulo J. de Sa J. Pignatelli J. (2006). Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study. J Am Acad Dermatol 55, 968–74.
28. Soos N. Shakery K. Mrowietz U. (2004). Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 5, 357–59.
29. Van Kaer L. (2011). Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players. Exp Neurol 227, 19–23.
30. Varkony H. Weinstein V. Klinger E. Sterling J. Cooperman H. Komlosh T. Ladkani D. Schwartz R. (2009). The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother, 10, 657–68.
31. Weber M. S. Hohlfeld R. Zamvil S. S. (2007). Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4, 647–53.